PT2734186T - Composição - Google Patents

Composição

Info

Publication number: PT2734186T
Authority: PT; Portugal
Prior art keywords: composition
Prior art date: 2011-07-22

Application number

PT12740119T

Other languages

English (en)

Inventor

Louise Ambery Claire

David Edwards Christopher

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-22

Filing date

2012-07-19

Publication date

2018-12-17

2012-07-19 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2018-12-17 Publication of PT2734186T publication Critical patent/PT2734186T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

PT12740119T 2011-07-22 2012-07-19 Composição PT2734186T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161510624P	2011-07-22	2011-07-22

Publications (1)

Publication Number	Publication Date
PT2734186T true PT2734186T (pt)	2018-12-17

Family

ID=46581948

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT12740119T PT2734186T (pt)	2011-07-22	2012-07-19	Composição

Country Status (19)

Country	Link
US (2)	US10112946B2 (pt)
EP (1)	EP2734186B1 (pt)
JP (1)	JP2014520874A (pt)
KR (1)	KR101916928B1 (pt)
CN (1)	CN103841958A (pt)
AU (2)	AU2012289042A1 (pt)
BR (1)	BR112014001425A2 (pt)
CA (1)	CA2841361A1 (pt)
CY (1)	CY1120802T1 (pt)
DK (1)	DK2734186T3 (pt)
ES (1)	ES2693122T3 (pt)
HR (1)	HRP20181667T1 (pt)
LT (1)	LT2734186T (pt)
PL (1)	PL2734186T3 (pt)
PT (1)	PT2734186T (pt)
RS (1)	RS57995B1 (pt)
RU (1)	RU2631482C2 (pt)
SI (1)	SI2734186T1 (pt)
WO (1)	WO2013014052A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA103195C2 (uk)	2008-08-11	2013-09-25	Глаксосмитклайн Ллк	Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
CN103841958A (zh)	2011-07-22	2014-06-04	葛兰素史克有限责任公司	组合物
AR092198A1 (es)	2012-08-24	2015-04-08	Glaxosmithkline Llc	Derivados de pirazolopirimidinas
US9550785B2 (en)	2012-11-20	2017-01-24	Glaxosmithkline Llc	Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
ES2625023T3 (es)	2012-11-20	2017-07-18	Glaxosmithkline Llc	Compuestos novedosos
HUE13857477T2 (hu)	2012-11-20	2018-05-28	Glaxosmithkline Llc	Új vegyületek

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW574214B (en)	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
US7125880B1 (en)	1995-06-06	2006-10-24	Pfizer Inc.	Corticotropin releasing factor antagonists
AU3176297A (en)	1996-06-25	1998-01-14	Novartis Ag	Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US5985848A (en)	1997-10-14	1999-11-16	Albert Einstein College Of Medicine Of Yeshiva University	Inhibitors of nucleoside metabolism
TW572758B (en)	1997-12-22	2004-01-21	Sumitomo Pharma	Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
AU3540101A (en)	2000-01-07	2001-07-16	Universitaire Instelling Antwerpen	Purine derivatives, process for their preparation and use thereof
DE60109148T2 (de)	2000-04-28	2006-01-05	Acadia Pharmaceuticals Inc., San Diego	Muscarinrezeptoren
GB0114286D0 (en)	2001-06-12	2001-08-01	Hoffmann La Roche	Nucleoside Derivatives
CA2457468A1 (en) *	2001-08-09	2003-02-27	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient
TW200301251A (en)	2001-12-20	2003-07-01	Wyeth Corp	Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
RU2217159C1 (ru) *	2002-03-18	2003-11-27	ООО "Содарм фарма"	Раствор для ингаляций фармацевтической композиции глутовент и способ его терапевтического применения
DE60237425D1 (de)	2002-03-28	2010-10-07	Univerzita Palackeho V Olomouc	PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
MXPA04010983A (es)	2002-05-06	2005-02-14	Genelabs Tech Inc	Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c.
US6713241B2 (en)	2002-08-09	2004-03-30	Eastman Kodak Company	Thermally developable emulsions and imaging materials containing binder mixture
SI1539783T1 (sl)	2002-08-21	2011-08-31	Einstein Coll Med	Inhibitorji nukleozidnih fosforilaz in nukleozidaz
BR0314761A (pt)	2002-09-27	2005-07-26	Sumitomo Pharma	Composto de adenina e seu uso
EP1646614A4 (en)	2003-07-01	2008-09-10	Merck & Co Inc	OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
WO2005020892A2 (en)	2003-08-08	2005-03-10	Mitochroma Research, Inc.	Pharmaceutical compositions and methods for metabolic modulation
NZ545536A (en)	2003-09-05	2010-04-30	Anadys Pharmaceuticals Inc	TLR7 ligands for the treatment of hepatitis C
NZ546274A (en)	2003-10-03	2009-12-24	3M Innovative Properties Co	Pyrazolopyridines and analags thereof
WO2005044354A1 (en)	2003-11-03	2005-05-19	Glaxo Group Limited	A fluid dispensing device
RU2397171C2 (ru)	2004-03-26	2010-08-20	ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД.	9-замещенное производное 8-оксоаденина и лекарственное средство
US20070225303A1 (en)	2004-03-26	2007-09-27	Haruhisa Ogita	8-Oxoadenine Compound
WO2005097800A1 (en)	2004-04-02	2005-10-20	Osi Pharmaceuticals, Inc.	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2005110410A2 (en)	2004-05-14	2005-11-24	Abbott Laboratories	Kinase inhibitors as therapeutic agents
US20060029642A1 (en)	2004-08-03	2006-02-09	Dusan Miljkovic	Methods and compositions for improved chromium complexes
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
JP2008540396A (ja)	2005-05-04	2008-11-20	ファイザー・リミテッド	癌およびｃ型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての２−アミド−６−アミノ−８−オキソプリン誘導体
NZ540160A (en)	2005-05-20	2008-03-28	Einstein Coll Med	Inhibitors of nucleoside phosphorylases
CA2615946A1 (en)	2005-07-22	2007-02-01	Sunesis Pharmaceuticals, Inc.	Pyrazolo pyrimidines useful as aurora kinase inhibitors
EP1931352B1 (en)	2005-08-22	2016-04-13	The Regents of The University of California	Tlr agonists
US8003624B2 (en)	2005-08-25	2011-08-23	Schering Corporation	Functionally selective ALPHA2C adrenoreceptor agonists
US7803828B2 (en)	2005-08-25	2010-09-28	Schering-Plough Corporation	Functionally selective alpha2C adrenoreceptor agonists
RS20080128A (en)	2005-09-02	2009-05-06	Pfizer Inc.,	Hydroxy substituted 1h-imidazopyridines and methods
TW200801003A (en)	2005-09-16	2008-01-01	Astrazeneca Ab	Novel compounds
WO2007034817A1 (ja)	2005-09-22	2007-03-29	Dainippon Sumitomo Pharma Co., Ltd.	新規アデニン化合物
TW200745114A (en)	2005-09-22	2007-12-16	Astrazeneca Ab	Novel compounds
US20090105212A1 (en)	2005-09-22	2009-04-23	Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan	Novel adenine compound
US20090099216A1 (en)	2005-09-22	2009-04-16	Astrazeneca Aktiebolag A Corporation Of Sweden	Novel adenine compound
US20080269240A1 (en)	2005-09-22	2008-10-30	Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan	Novel Adenine Compound
EP1939198A4 (en)	2005-09-22	2012-02-15	Dainippon Sumitomo Pharma Co	NEW ADENINE CONNECTION
CN1947717B (zh)	2005-10-14	2012-09-26	卓敏	选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
CA2640672A1 (en)	2006-02-17	2007-08-23	Pfizer Limited	3 -deazapurine derivatives as tlr7 modulators
EP2010505B1 (en)	2006-03-28	2012-12-05	Atir Holding S.A.	Heterocyclic compounds and uses thereof in the treatment of sexual disorders
GB0610666D0 (en) *	2006-05-30	2006-07-05	Glaxo Group Ltd	Fluid dispenser
CA2653941C (en)	2006-05-31	2013-01-08	The Regents Of The University Of California	Substituted amino purine derivatives and uses thereof
EP2041135A4 (en)	2006-07-05	2010-12-01	Astrazeneca Ab	As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK
WO2008005555A1 (en)	2006-07-07	2008-01-10	Gilead Sciences, Inc.	Modulators of toll-like receptor 7
TW200831105A (en)	2006-12-14	2008-08-01	Astrazeneca Ab	Novel compounds
SI2125792T1 (sl)	2007-02-19	2011-03-31	Glaxosmithkline Llc	Purinski derivati kot imunomodulatorji
WO2008114006A1 (en)	2007-03-19	2008-09-25	Astrazeneca Ab	9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
SI2132209T1 (sl)	2007-03-19	2014-05-30	Astrazeneca Ab	Spojine 9-substituiranega-8-okso-adenina, kot modulatorji Toll-like receptorja (TLR7)
JPWO2008114819A1 (ja)	2007-03-20	2010-07-08	大日本住友製薬株式会社	新規アデニン化合物
PE20081887A1 (es)	2007-03-20	2009-01-16	Dainippon Sumitomo Pharma Co	Nuevo compuesto de adenina
US7928111B2 (en)	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
TWI434849B (zh)	2007-06-29	2014-04-21	Gilead Sciences Inc	類鐸（Ｔｏｌｌ－ｌｉｋｅ）受體７之調節劑
GB0715087D0 (en)	2007-08-03	2007-09-12	Summit Corp Plc	Drug combinations for the treatment of duchenne muscular dystrophy
JP2010535773A (ja)	2007-08-10	2010-11-25	グラクソスミスクラインエルエルシー	ウイルス感染を治療するための窒素含有二環式化学物質
UY31531A1 (es)	2007-12-17	2009-08-03		Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
WO2009151910A2 (en)	2008-05-25	2009-12-17	Wyeth	Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8946239B2 (en)	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
EP2326646B1 (en)	2008-08-11	2013-07-31	GlaxoSmithKline LLC	Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
WO2010018132A1 (en)	2008-08-11	2010-02-18	Smithkline Beecham Corporation	Compounds
CN102203095A (zh)	2008-08-11	2011-09-28	葛兰素史密丝克莱恩有限责任公司	用于治疗变应性疾病、炎性疾病和感染性疾病的嘌呤衍生物
US8802684B2 (en)	2008-08-11	2014-08-12	Glaxosmithkline Llc	Adenine derivatives
SG193149A1 (en) *	2008-08-11	2013-09-30	Glaxosmithkline Llc	Novel adenine derivatives
UA103195C2 (uk)	2008-08-11	2013-09-25	Глаксосмитклайн Ллк	Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
CN102548999A (zh)	2009-01-20	2012-07-04	山东轩竹医药科技有限公司	含有取代的含氮稠杂环的头孢菌素衍生物
WO2010111406A2 (en)	2009-03-24	2010-09-30	Myriad Pharmaceuticals, Inc.	Compounds and therapeutic uses thereof
ES2732999T3 (es)	2009-08-07	2019-11-27	Glaxosmithkline Biologicals Sa	Derivados de oxoadenina lipidada
WO2011098451A1 (en)	2010-02-10	2011-08-18	Glaxosmithkline Llc	Purine derivatives and their pharmaceutical uses
PT2534149E (pt)	2010-02-10	2014-12-23	Glaxosmithkline Llc	Maleato de 6-amino-2-{[(1s)-1-metilbutil]oxi}-9-[5-(1- piperidinil)pentil]-7,9-di-hidro-8h-purin-8-ona
WO2012009258A2 (en)	2010-07-13	2012-01-19	Edward Roberts	Peptidomimetic galanin receptor modulators
WO2012092552A1 (en)	2010-12-30	2012-07-05	Selecta Biosciences, Inc.	Synthetic nanocarriers with reactive groups that release biologically active agents
ES2734878T3 (es)	2011-02-01	2019-12-12	Univ Illinois	Derivados de N-hidroxibenzamida como inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
US9139590B2 (en)	2011-02-04	2015-09-22	Duquesne University Of The Holy Spirit	Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
CN103841958A (zh)	2011-07-22	2014-06-04	葛兰素史克有限责任公司	组合物
AR092198A1 (es)	2012-08-24	2015-04-08	Glaxosmithkline Llc	Derivados de pirazolopirimidinas
HUE13857477T2 (hu)	2012-11-20	2018-05-28	Glaxosmithkline Llc	Új vegyületek
ES2625023T3 (es)	2012-11-20	2017-07-18	Glaxosmithkline Llc	Compuestos novedosos
US9550785B2 (en)	2012-11-20	2017-01-24	Glaxosmithkline Llc	Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
CA2938476A1 (en)	2014-02-20	2015-08-27	Glaxosmithkline Intellectual Property (No.2) Limited	Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon

2012
- 2012-07-19 CN CN201280036096.6A patent/CN103841958A/zh active Pending
- 2012-07-19 ES ES12740119.8T patent/ES2693122T3/es active Active
- 2012-07-19 BR BR112014001425A patent/BR112014001425A2/pt not_active IP Right Cessation
- 2012-07-19 KR KR1020147004436A patent/KR101916928B1/ko active IP Right Grant
- 2012-07-19 JP JP2014520661A patent/JP2014520874A/ja active Pending
- 2012-07-19 SI SI201231421T patent/SI2734186T1/sl unknown
- 2012-07-19 DK DK12740119.8T patent/DK2734186T3/en active
- 2012-07-19 RS RS20181346A patent/RS57995B1/sr unknown
- 2012-07-19 WO PCT/EP2012/064139 patent/WO2013014052A1/en active Application Filing
- 2012-07-19 LT LTEP12740119.8T patent/LT2734186T/lt unknown
- 2012-07-19 EP EP12740119.8A patent/EP2734186B1/en active Active
- 2012-07-19 US US14/234,070 patent/US10112946B2/en not_active Expired - Fee Related
- 2012-07-19 PT PT12740119T patent/PT2734186T/pt unknown
- 2012-07-19 PL PL12740119T patent/PL2734186T3/pl unknown
- 2012-07-19 RU RU2013157398A patent/RU2631482C2/ru not_active IP Right Cessation
- 2012-07-19 AU AU2012289042A patent/AU2012289042A1/en not_active Abandoned
- 2012-07-19 CA CA2841361A patent/CA2841361A1/en not_active Abandoned
2016
- 2016-04-20 AU AU2016202513A patent/AU2016202513B2/en not_active Ceased
2018
- 2018-09-27 US US16/143,969 patent/US20190023707A1/en not_active Abandoned
- 2018-10-12 HR HRP20181667TT patent/HRP20181667T1/hr unknown
- 2018-10-31 CY CY181101125T patent/CY1120802T1/el unknown

Also Published As

Publication number	Publication date
AU2016202513B2 (en)	2018-03-22
SI2734186T1 (sl)	2018-11-30
RU2631482C2 (ru)	2017-09-22
CY1120802T1 (el)	2019-12-11
AU2012289042A1 (en)	2014-03-13
US20140288099A1 (en)	2014-09-25
KR101916928B1 (ko)	2018-11-08
EP2734186A1 (en)	2014-05-28
BR112014001425A2 (pt)	2017-11-21
ES2693122T3 (es)	2018-12-07
PL2734186T3 (pl)	2019-01-31
CN103841958A (zh)	2014-06-04
HRP20181667T1 (hr)	2018-12-14
LT2734186T (lt)	2018-12-10
RU2013157398A (ru)	2015-08-27
WO2013014052A1 (en)	2013-01-31
CA2841361A1 (en)	2013-01-31
KR20140049001A (ko)	2014-04-24
US10112946B2 (en)	2018-10-30
RS57995B1 (sr)	2019-01-31
JP2014520874A (ja)	2014-08-25
EP2734186B1 (en)	2018-09-12
DK2734186T3 (en)	2019-01-07
US20190023707A1 (en)	2019-01-24

Publication	Publication Date	Title
ZA201400330B (en)	2022-03-30	Novel composition
ZA201308399B (en)	2015-01-28	Improved composition
EP2730619A4 (en)	2015-02-18	COMPOSITION
HRP20181667T1 (hr)	2018-12-14	Pripravak
EP2692796A4 (en)	2014-09-17	COMPOSITION
GB201120616D0 (en)	2012-01-11	Composition
IL231660A0 (en)	2014-05-28	preparation
GB201119601D0 (en)	2011-12-28	Composition
HK1201029A1 (en)	2015-08-21	Composition
GB201121258D0 (en)	2012-01-18	Composition
GB201108912D0 (en)	2011-07-13	Composition
GB201103964D0 (en)	2011-04-20	Composition
GB201204957D0 (en)	2012-05-02	Composition
GB201115211D0 (en)	2011-10-19	Composition
ZA201309110B (en)	2015-03-25	Composition
GB201216884D0 (en)	2012-11-07	Composition
ZA201203742B (en)	2013-02-27	Nutricosmetic composition
GB201322023D0 (en)	2014-01-29	Composition
EP2711011A4 (en)	2014-11-05	PANAXADIUM-CONTAINING COMPOSITION
GB201118701D0 (en)	2011-12-14	Composition
GB201121300D0 (en)	2012-01-25	Novel composition
GB201118516D0 (en)	2011-12-07	Composition
GB201117232D0 (en)	2011-11-16	Composition
GB201116970D0 (en)	2011-11-16	Composition
GB201116817D0 (en)	2011-11-09	Composition